Engineering botulinum neurotoxin to extend therapeutic intervention.
about
SNAP-23 and VAMP-3 contribute to the release of IL-6 and TNFα from a human synovial sarcoma cell lineCurrent status and future directions of botulinum neurotoxins for targeting pain processingTNFα induces co-trafficking of TRPV1/TRPA1 in VAMP1-containing vesicles to the plasmalemma via Munc18-1/syntaxin1/SNAP-25 mediated fusion.Diversity and impact of prokaryotic toxins on aquatic environments: a reviewAirway mucus function and dysfunction.Syntaxin requirement for Ca2+-triggered exocytosis in neurons and endocrine cells demonstrated with an engineered neurotoxin.Embryonic stem cell-derived motoneurons provide a highly sensitive cell culture model for botulinum neurotoxin studies, with implications for high-throughput drug discoveryUnique ganglioside binding by botulinum neurotoxins C and D-SATowards new uses of botulinum toxin as a novel therapeutic toolSNAP23 is selectively expressed in airway secretory cells and mediates baseline and stimulated mucin secretion.Clinical uses of botulinum neurotoxins: current indications, limitations and future developmentsProteases as therapeutics.Molecular structures and functional relationships in clostridial neurotoxins.Targeted secretion inhibitors-innovative protein therapeuticsClostridial neurotoxins: mechanism of SNARE cleavage and outlook on potential substrate specificity reengineering.The blockade of the neurotransmitter release apparatus by botulinum neurotoxins.Re-assembled botulinum neurotoxin inhibits CNS functions without systemic toxicity.Botulinum protease-cleaved SNARE fragments induce cytotoxicity in neuroblastoma cells.Stapling of the botulinum type A protease to growth factors and neuropeptides allows selective targeting of neuroendocrine cellsBotulinum Neurotoxins: Biology, Pharmacology, and Toxicology.Engineered botulinum neurotoxin B with improved efficacy for targeting human receptorsCrystal structures of OrfX2 and P47 from a Botulinum neurotoxin OrfX-type gene cluster.Soluble N-Ethylmaleimide-Sensitive Factor Attachment Protein Receptor-Derived Peptides for Regulation of Mast Cell Degranulation.Structural and biochemical characterization of the protease domain of the mosaic botulinum neurotoxin type HA.Engineering botulinum neurotoxin domains for activation by toxin light chain.Targeted Delivery of Protein Drugs by Nanocarriers.Aminopeptidase secreted by Chromobacterium sp. Panama inhibits dengue virus infection by degrading the E protein.Novel Botulinum Neurotoxins: Exploring Underneath the Iceberg Tip.Engineering Botulinum Toxins to Improve and Expand Targeting and SNARE Cleavage ActivityStudying the differential efficacy of postsymptom antitoxin treatment in type A versus type B botulism using a rabbit spirometry model
P2860
Q24316444-20BA4B51-C66E-4748-9119-5165AAF2DEA4Q26778129-CC707C53-B63D-46B0-B0A4-0B1D998B9FC0Q27348801-1F38974D-70B7-47E8-A2C2-29ED51BDE9DCQ28741635-4AD52F95-142C-45F0-98C3-5F784CC259F1Q33723578-8867CD97-64D2-4C87-9BCB-0C4A4F619706Q34769128-44DE8523-6871-4E4A-8081-347FDEE7657AQ34850583-27146883-AD42-4546-AFFD-501F32834C47Q35207347-FD64932E-5D71-42EC-A1C0-3DCFA80A1F13Q35534477-9D05ECCC-D134-48CB-88CD-1E6F00EFA4B8Q36185065-AC0729E1-C17A-4573-AAB4-CA0FA33D919DQ36395728-777C12C2-E788-4813-97D3-E9568A94FE6AQ37853216-9AC8F937-29B8-4889-ADF3-21011A67486DQ37876965-1A24E1CA-C181-4E01-AF09-E01DD1A55B17Q37954277-5CC50694-C1F5-4744-8DD4-C935D6FEAF9EQ37954285-6326A891-7B3F-4DBA-820C-3C6E775BD601Q38113138-BEF82BEC-31CC-4F55-845E-6F4375846197Q38843144-5DB14A33-AC80-4510-A996-87277AAAEA0FQ39039170-478A8EA0-D3E7-4D39-A814-31A1BFE7DE4DQ39157207-E396F404-6ED1-47CC-B487-22E0196526A0Q39207459-D731071A-5BFF-4FE6-B79D-FD1D8CA83197Q40971832-2F8B122A-44E7-4E14-BF58-38569C27F666Q47606877-94CABA8B-4E3D-47B4-A118-212C7D2AF438Q52309389-8918063B-78DF-4168-AF7F-F50AAE9D3EE0Q52567313-4D72B4B3-D409-4684-B3B6-D90ECCD7C402Q53201125-D6CEE5CD-40D8-4F2D-AED1-7105D83FF225Q54647504-E6F31235-4B4D-4179-AF91-A3031CE4DDBCQ55209557-092091B2-B627-46C0-99D0-B3368099D486Q55331839-0C35F48E-3331-4071-9E59-7A5F22BAB2CEQ57177243-5E87565F-795B-42AE-B178-492D8CCC233AQ59127632-07444C73-DC99-47C1-97CA-52C26D4BD6FC
P2860
Engineering botulinum neurotoxin to extend therapeutic intervention.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Engineering botulinum neurotoxin to extend therapeutic intervention.
@en
Engineering botulinum neurotoxin to extend therapeutic intervention.
@nl
type
label
Engineering botulinum neurotoxin to extend therapeutic intervention.
@en
Engineering botulinum neurotoxin to extend therapeutic intervention.
@nl
prefLabel
Engineering botulinum neurotoxin to extend therapeutic intervention.
@en
Engineering botulinum neurotoxin to extend therapeutic intervention.
@nl
P2860
P356
P1476
Engineering botulinum neurotoxin to extend therapeutic intervention
@en
P2093
Joseph T Barbieri
P2860
P304
P356
10.1073/PNAS.0903111106
P407
P50
P577
2009-06-01T00:00:00Z